Case series discussion of cardiac and vascular events following carfilzomib treatment: possible mechanism, screening, and monitoring

BACKGROUND: Carfilzomib is a selective proteasome inhibitor approved in the United States in 2012 for the treatment of relapsed and refractory multiple myeloma. Although cardiopulmonary and vascular events have been reported infrequently, they can be potentially serious complications, and their inci...

Descripción completa

Detalles Bibliográficos
Autores principales: Chari, Ajai, Hajje, Daher
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4289164/
https://www.ncbi.nlm.nih.gov/pubmed/25471129
http://dx.doi.org/10.1186/1471-2407-14-915

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4289164/
https://www.ncbi.nlm.nih.gov/pubmed/25471129
http://dx.doi.org/10.1186/1471-2407-14-915

Ejemplares similares